Introduction {#s1}
============

CNS macrophages can be broadly separated into three types: microglia, choroid plexus macrophages, and border-associated macrophages (BAMs) of the dura, subdura/pia and the perivascular space ([@bib19]; [@bib54]). Circulatory monocytes, which invade the CNS and differentiate into macrophages, are also present in the context of CNS injury and inflammation ([@bib44]). These different types of macrophages play fundamental roles in CNS development, homeostasis and disease, but their specific functions remain poorly defined. An important barrier to defining the subtype-specific functions of CNS macrophages has been a lack of genetic tools to specifically target these subpopulations, although there has been some progress in this regard in recent years ([@bib11]; [@bib52]; [@bib53]).

Microglia, the resident macrophages of the neural parenchyma, regulate a wide variety of processes in the brain, from development and synapse remodeling, to inflammatory insult and antigen presentation. Fate-mapping and developmental analyses have revealed that microglia are derived from the embryonic yolk sac, unlike circulating monocytes, which are derived from the adult bone marrow. Although bone marrow derived macrophages can adopt some features of endogenous microglia, they are not able to fully recapitulate all of their properties, suggesting that there may be important functional differences between these two populations of cells ([@bib6]). The use of single-cell transcriptomic profiling has revealed new insights about microglial biology in recent years ([@bib21]; [@bib27]; [@bib49]) suggesting a greater degree of heterogeneity among microglia than previously recognized. Recently developed microglial genetic labeling strategies, such as the mouse line *Cx3cr1-CreER* ([@bib18]; [@bib38]; [@bib56]), have significant advantages compared to their predecessors, but still have a number of drawbacks. For instance, *Cx3cr1* is expressed in other immune cell types in the brain, including perivascular, choroid plexus and meningeal macrophages ([@bib19]). Acute tamoxifen administration in *Cx3cr1-CreER* mice also labels circulating monocytes, which can infiltrate the CNS in the context of injury or disease, thus complicating interpretation. This can be circumvented by administering tamoxifen and then waiting for recombined circulating monocytes to be replaced by non-recombined monocytes from the bone marrow (\~15--30 days), so that only resident macrophages (e.g. BAMs and microglia) are recombined. Finally, *Cx3cr1-EGFP, -Cre and -CreER* mouse lines are haploinsufficient for *Cx3cr1,* as they were designed such that the *EGFP*, *Cre* or *CreER* coding regions replace the endogenous *Cx3cr1* coding region. There is evidence that *Cx3cr1* haploinsufficiency affects microglial function ([@bib25]; [@bib30]; [@bib41]), so these lines should be used with this caveat in mind.

Here, we describe a *P2ry12-CreER* knock-in mouse line that we have developed to specifically label microglia. P2RY12 is a nucleotide sensing metabotropic GPCR in the P2Y family of GPCRs that has an important role in the microglial 'sensome' ([@bib24]). P2RY12 has been shown to regulate the morphological changes that microglia display in response to tissue damage or inflammation ([@bib7]; [@bib23]). Here, we found that *P2ry12-CreER*, unlike the commonly used *Cx3cr1-CreER*, specifically labeled brain microglia and a subset of dural and choroid plexus macrophages, but not pial-associated or perivascular macrophages. During embryonic development, *P2ry12-CreER* recombination was robust in microglia, although we also observed recombination in a small subset of meningeal and perivascular macrophages, which we suggest may reflect cells that are in a 'transition' state. Using *P2ry12-CreER* with a conditionally expressed *Rpl22-HA* allele, we performed Cre-dependent ribosomal immunoprecipitations and transcriptional profiling of adult microglia. By comparing this dataset to existing ribosomal profiles of CNS macrophages and subtracting genes that are shared by both datasets, we identify a number of border-associated macrophage markers, including *Pf4*. Analysis of the *Pf4-Cre* mouse line shows that *Pf4-Cre* recombination robustly labels BAMs and not microglia. Finally, we show that *P2ry12-CreER* can be used to label microglia in middle cerebral artery occlusion (MCAO)-induced ischemic stroke, as well as experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis.

Results {#s2}
=======

Generation of a P2ry12-CreER mouse line {#s2-1}
---------------------------------------

To identify specific markers of brain microglia, we cross-referenced published reports of microglial markers ([@bib9]; [@bib16]; [@bib53]) with recently produced single cell sequencing data sets (Tabula Muris: <https://tabula-muris.ds.czbiohub.org>, Myeloid Cell Single Cell Seq database: <https://myeloidsc.appspot.com>). We analyzed several microglial markers (*HexB*, *P2ry12*, *Sall1*, *Tmem119, Trem2, Fcrls* and others) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), and compared their expression across cell types in the mouse body. Among these genes, *P2ry12* appeared to be the most restricted to brain myeloid cells.

To genetically label P2RY12+ microglia, we generated a *P2ry12-2A-CreER* knock-in mouse line (hereafter called *P2ry12-CreER*) ([Figure 1A](#fig1){ref-type="fig"}) using CRISPR-facilitated homologous recombination. The targeting construct was designed to preserve *P2ry12* expression, with the *P2ry12* stop codon replaced by a ribosome skipping P2A-fusion peptide coding sequence, followed by the coding sequence for *CreER*. We did not find any obvious health problems in either *P2ry12-CreER* heterozygous or homozygous mice, which had normal life span, breeding, size/weight, skin/hair, no overt neuromotor deficits, and no obvious bleeding abnormalities observed during tissue harvesting. We did see a decrease in *P2ry12* transcript levels in the brains of homozygous *P2ry12-CreER* knock-in mice, but this did not lead to differences in P2RY12 protein expression or noticeable changes in microglial morphology in gene targeted versus wild-type mice ([Figure 1---figure supplement 1A--C and E](#fig1s1){ref-type="fig"}).

![Microglia recombination by *P2ry12-CreER*.\
(**A**) Design of the *P2ry12* knock-in allele and a *P2ry12-CreER;Rosa26^Ai14^* mouse brain section immunostained for P2RY12 (cyan) and TdTomato (red). (**B**) Flow cytometry analysis of recombined TdTomato+ microglia in a *P2ry12-CreER;Rosa26^Ai14^* mouse. Microglia were pre-gated on forward scatter, isolation of single cells, and removal of dead cells. TdTomato+ cells are marked in red. 94.9 ± 2.75% of microglia (CD11b^+^CD45^int^ cells) were recombined by *P2ry12-CreER*. (**C-E**) Images of recombination in microglia of the cerebral cortex (**C**), spinal cord (**D**) cerebellum (**E**) in *P2ry12-CreER; Rosa26^Ai14^* mice. Sections stained with pan-macrophage marker IBA1 (green). (**F**) Immunohistochemical quantification of recombination in the cerebral cortex, spinal cord, hippocampus and cerebellum. For B-E, n = 3 mice. Error bars in F = standard error of the mean (SEM). Scale bars = 20 µm (**A**), 50 µm (**C**).\
Figure 1---source data 1.Microglial recombination by *P2ry12-CreER*.](elife-54590-fig1){#fig1}

P2ry12-CreER-mediated recombination efficiently and specifically labels microglia {#s2-2}
---------------------------------------------------------------------------------

To determine the efficiency and specificity of *P2ry12-CreER* recombination, we generated *P2ry12-CreER; Rosa26^Rosa26Ai14^* reporter mice, which express TdTomato upon Cre-dependent recombination ([@bib35]). There was very low, but not zero recombination in the absence of tamoxifen (.38±. 07% = of microglia,\~1 in 263, in the cerebral cortex of *P2ry12-CreER; Rosa26^Ai14^* heterozygotes, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). We suspect that this non-tamoxifen recombination rate will likely be lower for other floxed alleles, given the sensitivity of the Rosa26^Ai14^ reporter ([@bib2]). Following tamoxifen induction (3 injections of 150 µL 20 mg/mL tamoxifen in corn oil, delivered by oral gavage every other day) in adult mice we saw robust TdTomato expression in P2RY12^+^ microglia ([Figure 1A](#fig1){ref-type="fig"}). Analysis by flow cytometry of microglial recombination in the brain revealed that 94.9 ± 3.4% of microglia (CD11b^+^CD45^int^ cells) expressed TdTomato ([Figure 1B](#fig1){ref-type="fig"}). Immunohistochemical analysis showed similarly high levels of recombination in CNS IBA1+ microglia (90 ± 3.0% in the cerebral cortex, 82.7 ± 7.25% in the spinal cord, 89.2 ± 6.1% in the hippocampus and 88.0 ± 5.4% in the cerebellum)([Figure 1C--F](#fig1){ref-type="fig"}).

P2ry12-CreER-mediated recombination in border-associated macrophages (BAMs) {#s2-3}
---------------------------------------------------------------------------

To determine the specificity of *P2ry12-CreER*, we examined recombination in different subsets of border-associated macrophages ([Figure 2A](#fig2){ref-type="fig"}). We directed our initial analysis to LYVE1+, SMA-adjacent pial and perivascular macrophages. LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) is a membrane glycoprotein that marks the lymphatic vasculature, but is also expressed in meningeal and perivascular macrophages. Immunostaining thin coronal brain sections for LYVE1 and SMA (which marks mural smooth muscle cells around large brain vessels) revealed that *P2ry12-CreER; Rosa26^Ai14^* recombination did not mark LYVE1+ perivascular macrophages ([Figure 2B](#fig2){ref-type="fig"}), unlike *Cx3CR1-CreER; Rosa26^Ai14^* recombination ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Immunostaining for CD206 (MRC1), an additional marker of perivascular macrophages, also revealed no overlap with *P2ry12-CreER; Rosa26^Ai14^* recombination ([Figure 2D](#fig2){ref-type="fig"}). Similarly, we saw no *P2ry12-CreER; Rosa26^Ai14^* recombination in LYVE1+ macrophages of the pia ([Figure 2C](#fig2){ref-type="fig"}), unlike *Cx3cr1-CreER; Rosa26^Ai14^* ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In the choroid plexus, *P2ry12-CreER* recombination marked 21.8 ± 3.7% of IBA1^+^ cells, unlike *Cx3cr1-CreER*, which showed recombination in most choroid plexus IBA1^+^ macrophages ([Figure 2E,J](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). *P2ry12-CreER; Rosa26^Ai14^* recombined cells appeared to be on the surface of the choroid plexus, consistent with a recently published study that described a microglia-like, *P2ry12*-expressing 'CP-epi' subpopulation of choroid plexus macrophages, which may be Kolmer's epiplexus cells ([@bib31]; [@bib49]).

![Analysis of *P2ry12-CreER* recombination in brain macrophage populations.\
(**A**) Cartoon depicting the subsets of brain macrophage populations that were analyzed in *P2ry12-CreER; Rosa26^Ai14^* mice. D-BAMs, SD-BAMs, CP-BAMs = dural, subdural, choroid plexus border-associated macrophages. PVMs = perivascular macrophages. Adapted, with permission, from [@bib49]. (**B**) Analysis of *P2ry12-CreER; Rosa26^Ai14^* recombination in SMA-adjacent LYVE1+ perivascular macrophages. No recombination was seen in perivascular macrophages, unlike *Cx3CR1-CreER; Rosa26^Ai14^* mice (see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). (**C**) Analysis of recombination in LYVE1+ pial macrophages. ERTR7 expression delineates pial boundaries. (**D**) Analysis of recombination in SMA-adjacent CD206+ perivascular macrophages. (**E**) Analysis of recombination in IBA1+ macrophages of the choroid plexus. (**F**) Whole-mount cerebral cortex and dura, immunostained for CD206. (**G**) Whole-mount cerebral cortex and dura, immunostained for LYVE1. Weakly red cells in pial images are microglia in deeper focal planes. (**H--I**) Quantification of recombination in CD206+ (**H**) and LYVE1+ (**I**) macrophages in the parenchymal, pial and dural spaces. (**J**) Quantification of recombination in IBA1+ macrophages of the choroid plexus. Error bars = SEM. Scale bars = 100 µm (**B--G**).\
Figure 2---source data 1.Analysis of P2ry12-CreER recombination in brain macrophage populations.](elife-54590-fig2){#fig2}

To better examine meningeal recombination in *P2ry12-CreER; Rosa26^Ai14^* mice, we performed whole-mount immunostaining of these tissues according to published methods ([@bib49]). Labeling these preparations for two different BAM markers (LYVE1 and CD206) showed that *P2ry12-CreER; ROSA26^AI14^* recombination occurred in a subset of macrophages in the dura mater (24.3 ± 2.6% of CD206+ and 25.0 ± 0.9% of LYVE1+ macrophages), but did not recombine macrophages of the pia mater or perivascular space ([Figure 2F--I](#fig2){ref-type="fig"} and [Figure 2---video 1](#fig2video1){ref-type="video"}).

P2ry12-CreER recombination efficiently labels embryonic microglia {#s2-4}
-----------------------------------------------------------------

In our previous studies, we noted that P2RY12 expression is developmentally regulated, increasing in the brain throughout embryonic and early post-natal development ([@bib3]). To determine whether *P2ry12-CreER* was capable of recombining embryonic macrophages, we induced pregnant dams carrying *P2ry12-CreER; Rosa26^Ai14^* pups with a series of three tamoxifen doses at E13.5, E15.5, and E17.5 ([Figure 3A](#fig3){ref-type="fig"}). We collected these pups at E18.5 and analyzed their degree and pattern of recombination. Examination of these brains revealed robust recombination in IBA1^+^ parenchymal microglia; all microglia examined were TdTomato+. IBA1+ recombined microglia were most densely concentrated in the subventricular zone of the cortex (SVZ) and lateral migratory stream of the amygdala ([Figure 3B--B'', C,F](#fig3){ref-type="fig"}). Compared to the adult choroid plexus, we observed a larger percentage of recombination in macrophages of the embryonic choroid plexus (41.9 ± 5.8% of IBA1+ cells in the embryos vs 21.8 ± 3.7% in the adult) ([Figure 3K](#fig3){ref-type="fig"}). We also observed a low level of recombination in the embryonic meninges (8.0 ± 3.1% of CD206+ cells, 12.9 ± 2.5% of LYVE1+ cells). In contrast to adult *P2ry12CreER; Rosa26^Ai14^* mice, we observed recombination in macrophages apposed to nascent cerebral arteries. ([Figure 3H](#fig3){ref-type="fig"}). We did not observe any obvious recombination in the blood (embryos were not perfused prior to immersion fixation), vascular endothelium, or in other cell types in the brain at this age.

![*P2ry12-CreER* recombination in the embryonic brain.\
(**A**) Diagram of *P2ry12-CreER; Rosa26^Ai14^* embryonic tamoxifen induction regimen. Pregnant mice were induced with tamoxifen at E13.5, E15.5 and E17.5. Embryos were collected at E18.5. (**B**) Recombination in the E18.5 brain, shown in three images, arranged rostral (**B**) to caudal (**B''**). (**C**) *P2ry12-CreER; Rosa26^Ai14^* recombination in the developing cerebral cortex. Recombination was seen primarily in the parenchyma of the brain, with low levels of recombination in the meninges (arrowhead). This is quantified in I and J. (**D**) Recombination in LYVE1+ cells of the embryonic meninges (arrowheads). Recombination in microglia is noted with asterisks. (**E**) Recombination in IBA1+ cells of the choroid plexus, quantified in K. (**F**) Recombination was most concentrated in IBA1+ cells of the hippocampal and cortical SVZ (arrowheads). (**G**) CD206 staining of recombined cells of the hippocampal SVZ and cortical SVZ. CD206 expression was lower, and coexpression with TdT less frequent, with greater distance from the hippocampus. (**H**) Recombination was observed in SMA-adjacent CD206+ perivascular macrophages at E18.5 (arrowheads). (**I--J**) Quantification of recombination in meningeal CD206+ (**I**) and LYVE1+ (**J**) macrophages. (**K**) Quantification of recombination in embryonic choroid plexus IBA1+ macrophages. Cx = Cortex, LGE = lateral ganglionic eminence, LS = Lateral migratory stream, Str = Striatum, Th = Thalamus, SVZ = Subventricular zone. Scale bars = 800 µm (**B**), 400 µm (**C, F**), 100 µm (**D, G, H**), 200 µm (**E**).\
Figure 3---source data 1.P2ry12-CreER recombination in the embryonic brain.](elife-54590-fig3){#fig3}

In our immunostains of recombined E18.5 embryonic brains with CD206, we also noticed a population of recombined TdT+; CD206+ cells in the embryonic hippocampus and cortical SVZ ([Figure 2G](#fig2){ref-type="fig"}). These double positive cells were most frequent at the junction of the developing hippocampus and the overlying meninges (arrowheads in [Figure 3G](#fig3){ref-type="fig"}), but were also found in the hippocampal and cortical SVZ. CD206 expression was strongest in the hippocampus in cells that were radially aligned relative to the overlying meninges (arrow in [Figure 3G](#fig3){ref-type="fig"}). With greater distance from the hippocampus, CD206 expression in the SVZ was less frequent and intense, possibly indicating active down-regulation of CD206 in infiltrating meningeal macrophages as they migrate through the hippocampal and cortical SVZ (see discussion).

Expression of P2ry12-CreER in other tissues and blood {#s2-5}
-----------------------------------------------------

To determine the specificity of *P2ry12-CreER*-mediated recombination, we examined recombination in non-microglial cell types in the brain, circulation and in a variety of organs. In the brain, we saw no recombination in macroglia (oligodendrocytes and astrocytes), or neurons ([Figure 4A](#fig4){ref-type="fig"}). In the heart, intestine, lungs and spleen, TdTomato expression was limited to a small subset of CD206+ Cx3cr1-EGFP+ cells, suggesting that *P2ry12* expression marks a subset of macrophages in these tissues ([Figure 4B](#fig4){ref-type="fig"} and quantification in 4C). The kidney did not show any TdTomato expression (not shown). In the thymus, *P2ry12-CreER; Rosa26^Ai14^* recombination partially overlapped with Cx3cr1-EGFP and CD206+. The most prominent non-CNS recombination was in the spleen, where recombination was moderate (27.5 ± 5.8% of Cx3cr1-EGFP+ cells of the marginal zone and white pulp) and primarily restricted to CD206+; Cx3cr1-EGFP+ cells of the marginal zone between the red and white pulp, an area that contains macrophages that surveil the bloodstream, although there were a small number of TdT+ cells in the white pulp as well ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}; [@bib8]). In the liver, *P2ry12-CreER; Rosa26^Ai14^* recombination was excluded from perivascular SMA-adjacent Cx3CR1-EGFP cells, but was seen in Kupffer cells, in line with previous reports that Kupffer cells lack Cx3cr1 expression ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}; [@bib56]). Unlike the liver, *P2ry12-CreER; Rosa26^Ai14^* recombined cells in the lungs were close to SMA-demarcated airways and associated blood vessels ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). In an analysis of *P2ry12-CreER; Rosa26^Ai14^* recombination in embryonic tissue, we did not see any recombination in the embryonic liver or heart. In the intestine and heart, we saw low levels of recombination that partially overlapped with CD206 and IBA1 ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

![*P2ry12-CreER* recombination in non-microglial populations.\
(**A**) Analysis of *P2ry12-CreER; Rosa26^Ai14^* recombination showed a lack of recombination in oligodendrocytes (OLIG2), astrocytes (SOX9) or neurons (NEUN). (**B**) Analysis of recombination and coexpression with Cx3cr1-EGFP and CD206 in the spleen, lungs, heart, thymus, intestine and liver of adult *P2ry12-CreER; Rosa26^Ai14^; Cx3cr1-EGFP* mice. (**C**) Quantification of recombination overlap with Cx3CR1-EGFP (heart, intestine, lungs, spleen, thymus) or CD206 (heart, intestine, lungs). CD206 coexpression in the spleen and thymus was not analyzed due to density of CD206 expression. (**D**) Flow cytometry and blood smear recombination analysis revealed negligible recombination of blood cells in *P2ry12-CreER;Rosa26^Ai14^* mice compared to *Cx3cr1-EGFP* (internal control), or to *Cx3cr1-CreER; Rosa26^Ai14^* mice. \*p=0.0015, Student's t-test. N = 4 mice for A. and D., N = 3 mice for B and C. Scale bars = 50 µm (**A**), 100 µm (**B,D**).\
Figure 4---source data 1.P2ry12-CreER recombination in non-microglial populations.](elife-54590-fig4){#fig4}

To determine whether *P2ry12-CreER* recombines circulating blood cells and platelets, we examined recombination in *P2ry12-CreER; Rosa26^Ai14^* adult mice using blood smears and flow cytometry, one day after tamoxifen administration (same dosing as above). Blood smears of tamoxifen induced *P2ry12-CreER; Rosa26^Ai14^; Cx3Cr1-EGFP* mice showed no recombination in circulating lymphocytes, but as an internal positive control, these mice did have numerous Cx3cr1-EGFP^+^CD45^+^CD11b^+^ circulating monocytes ([Figure 4D](#fig4){ref-type="fig"}). In contrast, smears of *Cx3cr1-CreER; Rosa26^Ai14^* mice showed TdTomato expression indicative of recombination in circulating monocytes. Flow cytometry of *P2ry12-CreER; Rosa26^Ai14^; Cx3Cr1-EGFP* mice showed that while there were significant numbers of EGFP+ monocytes (34.93 ± 2.6% of CD45^+^;CD11b^+^ cells), there was a lack of TdTomato^+^ circulating monocytes (.0175 ± 0.02% of CD45^+^;CD11b^+^ cells, 3 samples with 0 TdTomato^+^ cells, 1 sample with 2 TdTomato^+^ cells out of 2852 CD45^+^;CD11b^+^ monocytes). In comparison, *Cx3cr1-CreER; Rosa26^Ai14^* samples showed recombination in 20.3 ± 1.8% of CD45^+^;CD11b^+^ monocytes ([Figure 4D](#fig4){ref-type="fig"}). Surprisingly, we observed no evidence of platelet recombination, using platelet factor 4 *(Pf4)-Cre; Rosa26^Ai14^* mice (well known to recombine platelets) as a positive control ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). These data indicate that while *P2ry12-CreER* recombination labels sparse subsets of resident macrophages in organs other than the brain, it does not label circulating blood cells or platelets.

P2ry12-CreER-dependent ribosomal profiling enriches for transcripts of parenchymal microglia {#s2-6}
--------------------------------------------------------------------------------------------

We next studied the mRNA transcriptional profile of microglia using *P2ry12-CreER* mice. Classically, mRNA profiling of defined myeloid cell types requires preparation of single cell suspensions followed by cell sorting, RNA isolation and sequencing. These manipulations are inefficient and introduce bias, especially in macrophage populations, which are difficult to mechanically or enzymatically separate. Furthermore, microglia show significant transcriptional changes upon dissociation and sorting ([@bib20]) although some changes can be suppressed by treatment with the transcription inhibitor actinomycin D (ActD-Seq) ([@bib49]). To avoid these pitfalls, we performed TRAP-Seq (translating ribosome affinity purification followed by mRNA sequencing) ([@bib43]) which allows for cell-specific isolation of mRNA without these manipulations. We generated *P2ry12-CreER; Rpl22-HA* mice, which, upon recombination, express a hemagglutanin (HA) epitope tagged RPL22 riboprotein that can be isolated by immunoprecipitation ([Figure 5A](#fig5){ref-type="fig"}). Upon tamoxifen-induced recombination in *P2ry12-CreER; Rpl22-HA* mice, we found robust labeling of microglia, as shown by immunofluorescent costaining for HA and IBA1 ([Figure 5B](#fig5){ref-type="fig"}). After qPCR validation for enrichment of microglial transcripts, libraries from *P2ry12-CreER; Rpl22* immunoprecipitations were generated and sequenced (workflow in 5C). Analysis of the transcripts enriched in *P2ry12-CreER; Rpl22-HA* libraries revealed significant enrichment for many known microglial markers, but did not show enrichment for markers of other cell types, such as neurons, oligodendrocytes and astrocytes ([Figure 5D](#fig5){ref-type="fig"}). Of note, we performed these experiments prior to learning of dural macrophage recombination by *P2ry12-CreER* mice ([Figure 2](#fig2){ref-type="fig"}), and did not include the dura in our immunoprecipitations.

![Cre-dependent ribosomal profiling of microglia.\
(**A**) Diagram illustrating *P2ry12-CreER*-dependent recombination of the *Rpl22-HA* allele, used to perform cell-type specific ribosomal profiling. (**B**) Immunostaining of tagged microglia for HA (red) and IBA1 (green) shows strong Cre-dependent expression of *Rpl22-HA* in microglia. (**C**) Workflow diagram for Cre-dependent ribosomal profiling experiments. (**D**) A comparison of relative enrichment for cell-type specific markers from *P2ry12-CreER; Rpl22-HA* and *Cx3cr1-CreER; Rpl22-HA* ribosomal immunoprecipitations. (**E**) Genome-wide comparisons of relative enrichment following immunoprecipitation of ribosomes in *P2ry12-CreER; Rpl22-HA* and *Cx3cr1-CreER; Rpl22-HA* mice. Pan-macrophage markers in blue; presumptive microglial markers in pink; presumptive BAM markers in red.](elife-54590-fig5){#fig5}

The transcriptional profile of *P2ry12-CreER* recombined cells was quite similar to recently published profiles derived from *Cx3cr1-CreER; Rpl22-HA* immunoprecipitations ([@bib20]). By comparing the relative enrichment values for individual genes in our *P2ry12-CreER; Rpl22-HA* data (X axis, [Figure 5E](#fig5){ref-type="fig"}) to *Cx3cr1-CreER; Rpl22-HA* enrichment values for the same gene (Y axis, [Figure 5E](#fig5){ref-type="fig"}), we identified a number of enriched genes that were either common or unique to each dataset. Genes common to both datasets included macrophage markers such as *Spi1*, *Aif1 (which codes for IBA1)*, *Csf1r* and *Cd11b*. Genes specific for neurons, macroglia, vascular endothelium, and blood cells/platelets (not shown) were depleted in both datasets. In line with our histological and cell-sorting data, there were many genes enriched in *Cx3cr1-CreER; Rpl22-HA* IPs that were not enriched in *P2ry12-CreER; Rpl22-HA* IPs. Some of these genes have recently been identified in single-cell sequencing studies as BAM-specific markers ([@bib49]), suggesting that our comparison differentiates genes expressed in parenchymal microglia from those expressed in non-parenchymal macrophages in the CNS ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). This subtractive approach also identified a number of genes that were preferentially enriched in the *P2ry12-CreER; Rpl22-HA* population, which represent potential microglial-specific markers. As expected, *P2ry12* was in this group, as were a number of other *P2Y* family members, such as *Gpr34*, *P2ry13* and *P2ry6*.

Pf4-Cre recombination efficiently labels BAMs {#s2-7}
---------------------------------------------

One gene that significantly enriched in *Cx3cr1-CreER; Rpl22-HA* IPs but marked depletion in *P2ry12-CreER; Rpl22-HA* IPs was the gene *Pf4*, also known as *Cxcl4* ([Figure 5E](#fig5){ref-type="fig"}). *Pf4* was the first member of the chemokine family of small peptides to be discovered ([@bib12]). It is strongly expressed in platelet granules where it functions to promote blood coagulation, and is also expressed in monocyte/macrophage-lineage cells where it is involved in various physiologic and pathologic processes ([@bib1]; [@bib10]). In single cell and bulk transcriptomic studies, *Pf4* is highly enriched in all BAM subtypes ([@bib49]) and is expressed early in EMP lineage commitment ([@bib36]; [@bib48]). Our ribosomal profiling data suggested that *Pf4* would be a prime candidate gene for BAM-specific genetic labeling. To explore this, we analyzed the lineage of cells marked by *Pf4* expression in *Pf4-Cre* transgenic mice ([@bib40]; [@bib47]). In sharp contrast to *P2ry12CreER; Rosa26^Ai14^* recombination, we found that in *Pf4-Cre; Rosa26^Ai14^* mice, all CD206+LYVE1+ perivascular, pial and dural macrophages were recombined ([Figure 6A--B, D--H](#fig6){ref-type="fig"}). In the choroid plexus, we found a high degree of recombination that was specific to IBA1+ macrophages (80.9 ± 3.7% of IBA1+ cells) ([Figure 6C,I](#fig6){ref-type="fig"}). *Pf4-Cre; Rosa26^Ai14^* mice also had a low degree of microglial recombination (5.24 ± 0.8% by flow cytometry, see [Figure 6F](#fig6){ref-type="fig"}), which appeared as clumps of cells scattered throughout the brain (asterisk in [Figure 6A](#fig6){ref-type="fig"}), suggestive of sporadic recombination and subsequent clonal expansion. We also saw consistent recombination in a small population of what appear to be neurons in the anterior amygdala ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). As has been reported, we found strong recombination in other organs, (not shown, [@bib40]) and in platelets ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). Altogether, we used a comparative ribosomal profiling approach to identify *Pf4* as a highly specific marker of BAMs ([Figure 5E](#fig5){ref-type="fig"}); based on this, we characterized the *Pf4-Cre* recombinase line and demonstrate that it is a robust method for genetic recombination in BAMs.

![*PF4-Cre* robustly labels border-associated macrophages of the brain.\
(**A-C**) Analysis of *PF4-Cre; Rosa26^Ai14^* recombination in (**A**) LYVE1+ perivascular macrophages, (**B**) CD206+ perivascular macrophages, and (**C**) IBA1+ choroid plexus macrophages. Asterisk in **A**: recombination in a small cluster of microglia. (**D--E**) *PF4-Cre; Rosa26^Ai14^* whole-mount immunostaining of the cerebral cortex parenchyma, pia and dura for CD206 (**D**) and LYVE1 (**E**). (**F**) Flow cytometry quantification of microglial recombination in *PF4-Cre; Rosa26^Ai14^* mice. (**G--H**) Quantification of *PF4-Cre; Rosa26^Ai14^* recombination in (**G**) CD206+ and (**H**) LYVE1+ perivascular, pial and dural macrophages. (**I**) Quantification of *PF4-Cre; Rosa26^Ai14^* recombination in IBA1+ cells of the choroid plexus. Error bars = SE (**F--H**), SEM (**I**). Scale bars = A-E-100um.\
Figure 6---source data 1.Pf4-Cre robustly labels border-associated macrophages of the brain.](elife-54590-fig6){#fig6}

Use of P2ry12-CreER in disease models {#s2-8}
-------------------------------------

Some 'homeostatic' microglia signature genes, such as *P2ry12*, are downregulated with injury/disease or with aging ([@bib13]; [@bib50]; [@bib55]). This raised the possibility that by inducing *P2ry12-CreER; Rosa26^Ai14^* mice with tamoxifen prior to injury, microglia in these mice could be tracked by virtue of their expression of TdTomato, even though microglial P2RY12 expression may be reduced in areas of tissue damage. Furthermore, due to the specificity of *P2ry12-CreER*, we suspected that in the context of injury, *P2ry12-CreER* recombination could be used to distinguish homeostatic and disease-associated microglia from infiltrating myelogenous cells. To test this, we induced recombination in *P2ry12-CreER; Rosa26^Ai14^* mice and then studied these mice in two separate injury models: unilateral MCAO (middle cerebral artery occlusion), a model of ischemic stroke, and EAE (experimental autoimmune encephalomyelitis), a model of neuro-inflammatory injury similar to human multiple sclerosis.

For MCAO and EAE experiments, mice were induced with tamoxifen a week prior to injury, thus ensuring that despite any transcriptional changes in microglia post-injury, microglia would be genetically labeled and tracked by their TdTomato expression. Twenty-four hours after MCAO, mice were perfused, and brains were sectioned and immunostained for markers of microglial homeostasis (P2RY12, TMEM119). We also stained for CXCL10, a pro-inflammatory cytokine ([@bib17]; [@bib27]; [@bib51]). Remarkably, ischemia-associated microglia (amoeboid-like CXCL10+ cells lacking P2RY12 and TMEM119 protein expression) filled the lesion core ([Figure 7A--E](#fig7){ref-type="fig"}). In the ischemic penumbra, outside of the stroke core, microglia had reduced process ramification, reduced P2RY12 and TMEM119 protein expression, and less frequent or reduced CXCL10 expression ([Figure 7C--E](#fig7){ref-type="fig"}).

![Genetic labeling of microglia during MCAO-induced stroke.\
(**A-B**) Genetically labeled microglia analyzed following MCAO-induced stroke show significant downregulation of microglial markers P2RY12 (**A**) and TMEM119 (**B**) in the ischemic core and penumbra. For both (**A**) and (**B**), the contralateral control hemisphere is the left column, the stroke-affected ipsilateral hemisphere is the right column. (**C--D**) Higher magnification of contralateral control area of the striatum, the stroke penumbra and core. P2RY12 and TMEM119 expression is reduced in the penumbra, and almost completely lost in the stroke core. In the stroke core, microglia are larger and amoeboid. (**E**) The cytokine CXCL10 is significantly upregulated in microglia of the stroke core. Scale bars = 500 µm (**A,B**), 50 µm (**C--E**).](elife-54590-fig7){#fig7}

To track microglia in the context of EAE, we used *P2ry12-CreER; Rosa26^Ai14^; Cx3Cr1-EGFP* mice, and collected tissue samples 10 days post-EAE symptom onset. Spinal cords were collected, sectioned, and immunostained for EGFP and PU.1, a pan-myeloid transcription factor. At a gross level, we observed TdTomato+ microglia dispersed throughout inflammatory lesions (asterisk in [Figure 8A](#fig8){ref-type="fig"}). We observed a large number of amoeboid TdTomato+; Cx3cr1-EGFP+; PU.1+ microglia in EAE lesions (arrowhead in [Figure 8D](#fig8){ref-type="fig"}) in contrast to non-lesion areas of the spinal cord ([Figure 8C,E](#fig8){ref-type="fig"}). We also observed a large number of TdTomato-; PU.1+; Cx3cr1-EGFP- infiltrating myelogenous cells (asterisk in [Figure 8D](#fig8){ref-type="fig"}) and a smaller number of TdTomato-; PU.1+; Cx3cr1-EGFP+ potential infiltrating monocytes (open arrowhead in [Figure 8D](#fig8){ref-type="fig"}).

![Genetic labeling of microglia during EAE.\
(**A**) Spinal cord microglia labeled prior to induction of EAE are dispersed throughout inflammatory lesions (see asterisk). (**B**) EAE spinal cord lesion in a *P2ry12-CreER; Rosa26^Ai14^; Cx3cr1-EGFP* mouse that was given tamoxifen a week prior to EAE induction. Sections were immunostained for PU.1 (white) and Cx3cr1-EGFP (green). (**C**) Control, non-lesioned area of the spinal cord. (**D**) Higher magnification view of EAE lesion, showing microglia (closed arrowhead), Cx3Cr1-EGFP; TdTomato(-) potential infiltrating monocytes (open arrowhead), and TdTomato(-); EGFP(-); PU.1 (+) infiltrating myelogenous cells (asterisk). (**E**) Higher magnification view of a non-lesioned area of the spinal cord. Scale bars = 500 µm (**A**), 100 µm (**B,C**), 40 µm (**D,E**).](elife-54590-fig8){#fig8}

Discussion {#s3}
==========

Efficiency and specificity of P2ry12-CreER {#s3-1}
------------------------------------------

Here, we describe a new method for the genetic manipulation of microglia in the CNS. We show that *P2ry12-CreER* robustly and specifically recombines microglia using flow cytometry, immunohistochemistry and ribosomal profiling. We did, however, find recombination in a subset of dural and choroid plexus macrophages. We believe that these recombined cells in the choroid plexus are likely to be Kolmer's epiplexus cells, which express significant levels of *P2ry12* ([@bib49]). Whether the gene expression similarities between CNS microglia and Kolmer's epiplexus cells have any developmental basis or functional significance will be an interesting topic for future research. In the blood, we did not see any significant recombination of monocytes or platelets. In most organs of adult mice, there was little to no recombination, although in the spleen we did see significant levels of recombination in marginal zone macrophages. In embryos, we found that *P2ry12-CreER* robustly labels microglia, as well as a small fraction of meningeal and perivascular macrophages. We did not see recombination in any non-macrophage cell types in the embryonic brain. In addition, we did not observe recombination in the embryonic heart and liver, and found it only in a small fraction of lung and intestinal macrophages. Altogether, our data suggest that *P2ry12-CreER* is robust in embryonic and adult microglia, while recombination in non-CNS organs and border-associated macrophages is limited or not detected.

Of note, while we observed limited *P2ry12-CreER* recombination in CD206+ and LYVE1+ macrophages of the embryonic meninges, we saw significantly more recombination in CD206+ macrophages of the hippocampus. Interestingly, CD206+; TdTomato+ cells were most highly concentrated at the junction between the hippocampus and the overlying meninges. Continuous with the hippocampus, CD206+; TdTomato+ cells formed a 'stream' through the cortical SVZ, suggestive of preferential localization, or possibly migration. Possibilities for what these cells represent could fit a few different models: 1) 'transitionary' macrophages that express *P2ry12* while in border areas, which downregulate BAM genes as they enter the brain parenchyma; 2) developmental expression (or possibly continual expression, in the case of *P2ry12-CreER; Rosa26^Ai14^* recombined dural macrophages) of *P2ry12* in a subset of BAMs; or 3) expression of *P2ry12* in cells that are transitioning from microglial to BAM identity. The turnover and exchange of BAMs and microglia into and out of their specific niches, and the gene expression programs that these cells adopt, could in theory be quite dynamic. Related to these observations, a recent study found that CD206+ and CD206- macrophages of the CNS derive from distinct yolk sac progenitors ([@bib48]). Further lineage studies, ideally with BAM-specific *CreER* lines such as *Cd206-CreER* ([@bib37]) (See [Supplementary file 3](#supp3){ref-type="supplementary-material"} for a list of BAM-targeting mouse lines) should provide further light on this matter.

Comparison of P2ry12-CreER to existing microglial recombinase lines {#s3-2}
-------------------------------------------------------------------

In recent years, knock-in and transgenic mouse lines using the fractalkine receptor gene *Cx3cr1* (e.g. *Cx3cr1-Cre*, -*CreER* and -*eGFP*) have been some of the best and most frequently used tools for targeting microglia ([@bib18]; [@bib38]). However, *Cx3cr1*-based mouse lines mark BAM macrophages in addition to microglia. *Cx3cr1* is also expressed in circulating T cells, B cells, NK cells and monocytes, which means that in the context of injury, *Cx3CR1-Cre, CreER* and *EGFP* are incapable of distinguishing between resident macrophages and other invading immune cells ([@bib4]; [@bib15]; [@bib26]; [@bib32]). The tamoxifen-inducible *Cx3cr1-CreER* allele avoids this problem to a degree, but requires a significant waiting period after recombination for recombined circulating cells to be depleted. This waiting period is inconvenient for most models of CNS injury and is incompatible with time-sensitive studies, such as models of neonatal brain injury. In addition to issues regarding specificity, *Cx3cr1* knock-in alleles (*EGFP, Cre, and CreER*) ([@bib18]; [@bib38]) are also haploinsufficient for Cx3CR1, as they disrupt the endogenous *Cx3cr1* gene. The effects of the reduction of Cx3cr1 dosage may in turn affect microglial function ([@bib41]; [@bib25]; [@bib30]).

Aside from *Cx3cr1*, knock-in *EGFP* and *CreER* lines have been generated for the microglial-enriched transcription factor *Sall1* ([@bib9]). However, caveats for these lines exist, including the fact that *Sall1-EGFP* and *CreER* both disrupt the function of the *Sall1* gene, loss of which disrupts microglial identity, see [@bib9]. *Sall1-CreER* also marks a broad range of non-myeloid CNS cell types ([@bib11]; [@bib45]), possibly due to tamoxifen-independent recombination and strong neuroectodermal expression of *Sall1* during development ([@bib22]).

In addition to *Cx3CR1* and *Sall1*-based microglial recombinase lines, new *Tmem119*-targeted mouse alleles have been generated (*Tmem119-GFP, RFP, CreER*) ([@bib28]; [@bib42]). In terms of specificity, both *Tmem119-CreER* and --*GFP* appear to show low but not insignificant levels of recombination or expression in brain-derived CD11b+; C45int/hi myeloid cells (1.9% and 6.9% for *CreER* recombination and GFP expression respectively). In the circulating blood, no *Tmem119-GFP*(+) monocytes were reported, but 7 days after the last tamoxifen injection, 3% of circulating CD45(+) monocytes were labeled by *Tmem119-CreER.* Of note, this waiting period of 7 days differed from our blood flow cytometry analysis, which was performed the day after the last tamoxifen dose. In the neonatal P1 brain, *Tmem119-GFP* showed widespread expression overlapping with the vascular endothelial cell marker, CD31. In adulthood, prolonged administration of tamoxifen to *Tmem119-CreER* mice induced recombination in non-IBA1(+) cells. This recombination was quite strong in IBA1(-) meningeal cells and in cells adjacent to large penetrating blood vessels, likely representing meningeal and perivascular fibroblasts, respectively. Indeed, based on single cell sequencing, *Tmem119* is highly expressed in CNS resident fibroblasts (<http://betsholtzlab.org/VascularSingleCells/database.html>).

In contrast to these other models, the *P2ry12-CreER* line has a number of advantages: 1) the design of the *P2ry12-CreER* allele results in maintained gene expression from the endogenous locus, avoiding haploinsufficiency or null allele complications; 2) recombination is absent in non-myelogenous cells in the adult CNS; 3) recombination is absent in the adult circulation; 4) recombination in the embryonic mouse brain is robust, with low levels of recombination in CD206+ and LYVE1+ cells; 5) *P2ry12-CreER* has very low levels of background recombination; and 6) recombination in non-CNS organs in the adult and embryo appears to be limited, except for moderate levels of recombination observed in marginal zone macrophages of the adult spleen. In future studies, it will be interesting to see if additional microglial markers, such as *Gpr34*, *P2ry6, P2ry13, HexB, Siglec-H*, prove useful for recombinase-based microglial targeting ([@bib24]; [@bib29]).

P2ry12-CreER applications {#s3-3}
-------------------------

In addition to gene deletion studies or reporter-based tracking of microglia, one particularly useful application of the *P2ry12-CreER* line is for Cre-dependent ribosomal profiling of microglia. Here, using a subtractive approach, we found a number of genes that had very high enrichment in *Cx3cr1-CreER; Rpl22-HA* samples but no enrichment in *P2ry12-CreER; Rpl22-HA* samples. Interestingly, some of these markers (*Mrc1*, *F13a1*, *Ms4a7* and *Mmp9*) were recently identified in other studies that used physical dissociation of the dural membranes from the neural parenchyma to separate BAMs from other CNS macrophage subtypes ([@bib27]; [@bib49]). One major drawback to strategies that rely on the physical dissection of these populations is that this process results in significant levels of cross contamination from microglia and other cells that that are in close contact with the meningeal layers. Furthermore, physical dissection of the meningeal layers does not separate perivascular macrophages of the penetrating vessels from the parenchymal microglia. In contrast, *P2ry12-CreER* recombination provides a more precise and complete genetic segregation of these populations that minimizes the transcriptional changes that are known to occur during sorting. The differential enrichment observed in our subtractive approach revealed several transcripts only expressed in BAMs. We focused on one such gene, *Pf4*, and found that *Pf4-Cre* robustly and preferentially recombines these cells.

The *P2ry12-CreER* mouse line is also particularly well suited for the labeling and tracking of microglia during CNS injury. One major barrier to studying microglia in the context of injury is that microglia undergo significant transcriptional changes in response to injury and/or inflammation, making it difficult to distinguish these microglia from other macrophage subtypes ([@bib20]; [@bib27]). These transcriptional changes are also induced by methods used to prepare microglia for analysis by flow cytometry. By genetically labeling and profiling microglia with *P2ry12-CreER* and TRAP-seq, these transcriptional changes associated with flow cytometry can be avoided ([@bib20]). Using *P2ry12-CreER*, transcriptional profiling or histochemical analysis of microglia can be performed at different stages of CNS injury, from the initial inflammatory response to later regenerative stages. Furthermore, due to the specificity of *P2ry12-CreER*, the contributions of CNS microglia can be parsed separately from invading peripheral monocytes.

In contrast to our EAE and MCAO microglial labeling strategy, in which microglia were labeled a week prior to injury, microglia could also be targeted in a tamoxifen-dependent manner during neuroinflammation. Although we have not yet tested this, we suspect that *P2ry12-CreER* recombination is likely to be reduced in inflammation-associated microglia, due to downregulation of *P2ry12*. Tamoxifen-dependent effects on neuroinflammation will be important to control for if this strategy is used ([@bib5]).

Conclusions and further directions {#s3-4}
----------------------------------

Here, we show by immunohistochemistry, flow cytometry, and ribosomal profiling that *P2ry12-CreER* has a number of advantages over existing microglial targeting *Cre* and *CreER* mouse lines. Using data derived from our Cre-dependent ribosomal profiles of microglia and analysis of the *Pf4-Cre* mouse line, we also show that *Pf4* is a highly specific marker of border-associated macrophages. We believe that the *P2ry12-CreER* allele will be particularly useful for conditional gene ablation in microglia, Cre-dependent transcriptional profiling, or reporter tracking studies of microglia. Going forward, new recombinase lines and new intersectional targeting strategies, such as dual Cre+Flp-dependent reporters ([@bib14]), will be critical for parsing the functional role of specific myeloid subpopulations in development and disease.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                              Designation                    Source or reference                      Identifiers                                                                                                         Additional\
  (species) or resource                                                                                                                                                                                                                  information
  ------------------------------------------ ------------------------------ ---------------------------------------- ------------------------------------------------------------------------------------------------------------------- -----------------
  Strain, strain background *Mus musculus*   *Cx3cr1-CreER*                 JAX                                      Stock No: 020940.\                                                                                                  
                                                                                                                     MGI: 5467985.                                                                                                       

  Strain, strain background *Mus musculus*   *Pf4-Cre*                      JAX                                      Stock No: 008535.\                                                                                                  
                                                                                                                     MGI: 3764698.                                                                                                       

  Antibody-linked beads                      Protein A Dynabeads            Invitrogen                               Catalog No: 10001D.                                                                                                 

  Chemical                                   Cyclohexamide                  Sigma                                    Catalog No: C7698-1G.                                                                                               

  Molecular biology reagent                  RNAse Inhibitor                New England BioLabs                      Catalog No: M0314S.                                                                                                 

  Molecular biology reagent                  Protease Inhibitors Cocktail   Sigma                                    Catalog No: S8830.                                                                                                  

  Antibody                                   Anti-CD11b-PECy7               BD Biosciences                           Rat monoclonal antibody. Catalog No: 561098. RRID:[AB_2033994](https://scicrunch.org/resolver/AB_2033994).          Used at 1:100.

  Antibody                                   Anti-CD206                     Biorad                                   Rat monoclonal antibody.\                                                                                           Used at 1:150.
                                                                                                                     Catalog No:\                                                                                                        
                                                                                                                     MCA2235T RRID:[AB_1101333](https://scicrunch.org/resolver/AB_1101333).                                              

  Antibody                                   Anti-CD45-APC                  BD Biosciences                           Rat monoclonal antibody. Catalog No: 559864.\                                                                       Used at 1:100.
                                                                                                                     RRID:[AB_398672](https://scicrunch.org/resolver/AB_398672).                                                         

  Antibody                                   Anti-CXCL10                    R and D Systems                          Goat polyclonal antibody. Catalog No: AF-466-NA.\                                                                   Used at 1:300.
                                                                                                                     RRID:[AB_2292487](https://scicrunch.org/resolver/AB_2292487).                                                       

  Antibody                                   Anti-EGFP                      Abcam                                    Chicken polyclonal antibody. Catalog No: ab13970. RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798).       Used at 1:300.

  Antibody                                   Anti-ERTR7                     Abcam                                    Rat monoclonal antibody. Catalog No:\                                                                               Used at 1:150.
                                                                                                                     Ab51824. RRID:[AB_881651](https://scicrunch.org/resolver/AB_881651).                                                

  Antibody                                   Anti-HA                        Cell Signaling                           Rabbit monoclonal antibody. Catalog No: C29F4. RRID:[AB_1549585](https://scicrunch.org/resolver/AB_1549585).        Used at 1:300.

  Antibody                                   Anti-IBA1                      Novus                                    Goat polyclonal antibody. Catalog No: NB100-1028. RRID:[AB_521594](https://scicrunch.org/resolver/AB_521594).       Used at 1:300.

  Antibody                                   Anti-LYVE1                     Abcam                                    Rabbit polyclonal antibody. Catalog No: ab14917. RRID:[AB_301509](https://scicrunch.org/resolver/AB_301509).        Used at 1:300.

  Antibody                                   Anti-NEUN                      Millipore                                Mouse monoclonal antibody. Catalog No: MAB377. RRID:[AB_2298772](https://scicrunch.org/resolver/AB_2298772).        Used at 1:100.

  Antibody                                   Anti-OLIG2                     Millipore                                Rabbit polyclonal antibody. Catalog No: AB9610. RRID:[AB_570666](https://scicrunch.org/resolver/AB_570666).         Used at 1:300.

  Antibody                                   Anti-P2RY12                    A generous gift from Dr. David Julius.   Rabbit polyclonal antibody.                                                                                         Used at 1:1000.

  Antibody                                   Anti-PU.1                      Cell Signaling                           Rabbit polyclonal antibody. Catalog No: 2266S.\                                                                     Used at 1:300.
                                                                                                                     RRID:[AB_10692379](https://scicrunch.org/resolver/AB_10692379).                                                     

  Antibody                                   Anti-SMA-647                   Santa Cruz Biotechnologies               Mouse monoclonal antibody. Catalog No:\                                                                             Used at 1:150.
                                                                                                                     Sc-32251. RRID:[AB_262054](https://scicrunch.org/resolver/AB_262054).                                               

  Antibody                                   Anti-SOX9                      R and D Systems                          Goat polyclonal antibody. Catalog No: AF3075. RRID:[AB_2194160](https://scicrunch.org/resolver/AB_2194160).         Used at 1:300.

  Antibody                                   Anti-TdTomato                  Chromotek                                Rat monoclonal antibody. Catalog No:5F8.\                                                                           Used at 1:500.
                                                                                                                     RRID:[AB_2336064](https://scicrunch.org/resolver/AB_2336064).                                                       

  Antibody                                   Anti-TdTomato                  Promega                                  Rabbit polyclonal antibody. Catalog No: \#632496. RRID:[AB_10013483](https://scicrunch.org/resolver/AB_10013483).   Used at 1:500.

  Antibody                                   Anti-TMEM119                   Abcam                                    Rabbit monoclonal antibody. Catalog No: ab209064. RRID:[AB_2800343](https://scicrunch.org/resolver/AB_2800343).     Used at 1:100.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*P2ry12-CreER* mice were generated by CRISPR-facilitated homologous recombination. The *P2ry12* coding sequence was joined to *CreER* by deletion of the *P2ry12* stop codon and in-frame 3' insertion of *P2A-CreER*. The P2A fusion peptide contains a 5' GSG motif, which has been shown to significantly increase fusion protein cleavage efficiency ([@bib46]). *P2ry12-CreER* mice were generated by pronuclear injection of the *P2ry12-CreER* targeting construct and a Cas9+gRNA expression plasmid (Biocytogen) into fertilized mouse eggs, followed by adoptive embryo transfer. Founder mice and progeny were screened by PCR, and proper genomic integration was verified by Southern blot and genomic sequencing. Recombination was induced by three doses of tamoxifen dissolved in corn oil, administered by oral gavage every other day (150 µL of 20 mg/mL). For embryonic mouse inductions, pregnant dams were given tamoxifen (150 µL of 20 mg/mL) on E13.5, E15.5 and E17.5, for a total of three gavage injections. All mouse work was performed in accordance with UCSF Institutional Animal Care and Use Committee protocols. Mice had food and water ad libitum. The *P2ry12-CreER* mouse line will be deposited at Jackson Labs (Stock \#034727) and at the Mutant Mouse Resource and Research Center (MMMRC).

Histology and immunostaining {#s4-2}
----------------------------

Mouse brains and other organs were harvested following transcardial perfusion with 20 mL cold PBS and 20 mL cold 4% formaldehyde. Tissue was fixed overnight at 4 degrees in 4% formaldehyde, followed by overnight incubation in 30% sucrose. Samples were embedded (Tissue Plus O.C.T. Compound, Fisher Scientific) and sectioned at 40 µm for adult tissues, and 20 µm for embryonic tissues. Whole-mount thin cortical sections and skull preparations were not incubated in sucrose, and immunostaining was started after a 2 hr 4% PFA post-fixation following perfusion and dissection. Sections or wholemount samples were immunostained using a blocking/permeabilization buffer of PBS containing 2% BSA, 5% donkey serum and. 5% TritonX-100. Primary and secondary antibodies were diluted in PBS containing 1% BSA and. 25% TritonX-100. Secondary antibodies conjugated to Alexa fluorophores were used at 1:300 (Jackson ImmunoResearch). Primary antibodies used included: SMA-647 (mouse monoclonal sc-32251, Santa Cruz Biotechnology, used at 1:150); Cd11b-PECy7 (BD Biosciences, used at 1:100); Cd45-APC (BD Biosciences, used at 1:100); CD206 (rat monoclonal, BioRad MCA2235T, used at 1:150); CXCL10 (goat polyclonal, R and D Systems AF-466-SP, used at 1:300); (ERTR7 (rat monoclonal, abcam ab51824, used at 1:300); EGFP (chicken polyclonal, abcam ab13970 used at 1:300); TdTomato (rat monoclonal, Chromotek, 5F8, used at 1:500); TdTomato (rabbit polyclonal, Living Colors DsRed Polyclonal \#632496, used at 1:1000); P2ry12 (rabbit polyclonal, kindly provided by Dr. David Julius, used at 1:1000); Iba1 (goat polyclonal, Novus NB100-1028, used at 1:300); Olig2 (rabbit polyclonal, Millipore, used at 1:300); NeuN (mouse monoclonal, Millipore MAB377, used at 1:100); Sox9 (goat polyclonal, R and D System AF3075, used at 1:300); Lyve1 (rabbit polyclonal, Abcam ab14917, used at 1:300); Pu.1 (rabbit polyclonal, Cell Signaling 2266S, used at 1:300); Tmem119 (rabbit monoclonal, Abcam ab209064); HA (rabbit monoclonal, Cell Signaling C29F4, used at 1:300). Cell counting in [Figure 1D](#fig1){ref-type="fig"} was performed on three mice, using three separate images taken from the spinal cord, cerebellum, cortex and hippocampus of each mouse.

Flow cytometry {#s4-3}
--------------

Microglial flow cytometry was performed using a percol gradient isolation strategy. To isolate single cells, brains were cut into small pieces and passed through a 40 µm filter. Single cell suspensions were prepared and centrifuged over a 30%/70% discontinuous Percoll gradient (GE Healthcare) and mononuclear cells were isolated from the interface. Flow cytometry was performed on a FACS Aria III using the FACSDiva 8.0 software (BD Biosciences) and was analyzed using FlowJo v10.6.1. TdTomato+ cells were analyzed for CD45 and CD11b expression following initial gatings for forward scatter, singlets and live cells. Blood smears and flow cytometry were performed on adult mice following three tamoxifen inductions as described above. Blood was collected from the facial vein and smears were imaged for EGFP and TdTomato expression. Prior to immunostaining, blood samples used for flow cytometry were depleted of erythrocytes using an ammonium chloride lysis buffer (.15M NH4Cl, 10 mM NaHCO3, 1.2 mM EDTA) wash. Blood flow cytometry was performed on a BD FACSVerse machine and analyzed using FlowJo v10.6.1.

Ribosomal immunoprecipitations {#s4-4}
------------------------------

Whole brains of *P2ry12-CreER; Rpl22-HA* and *Cx3cr1-Cre; Rpl22-HA* mice were dounce homogenized in 5 mL of homogenization buffer (1% NP-40, 0.1M KCL, 50 mM Tris pH 7.4, 0.02 mg/mL cycloheximide, 0.012M MgCl2, RNAse inhibitors, Heparin, 0.5 mM DTT). Tissue lysates were centrifuged at 10k-rcf for 10 min at four degrees to obtain a supernatant ribosomal fraction. An 80 µL input sample was taken at this point to serve as a comparison to immunoprecipitated samples. Rabbit monoclonal anti-HA antibody (Cell Signaling C29F4, 2.5 µL per mL) was added to the supernatant and incubated for 4 hr at four degrees. Iron-linked Protein A beads were added to the ribosomal fraction/antibody mixture (40 µL per mL) and incubated for an additional 4 hr before being magnetically precipitated. Immunoprecipitate/beads were washed with a high salt buffer (0.3M KCL, 1% NP-40, 50 mM Tris pH 7.4, 0.012M MgCL2, cyclohexamide, 0.5 mM DTT) three times and then eluted with 350 µL of buffer RLT (Qiagen RNeasy kit). Input and immunoprecipitated RNA was purified on column (Qiagen RNeasy kit) and frozen as aliquots at −80 degrees. cDNA from ribosomal immunoprecipitations was generated using Maxima First Strand cDNA Synthesis Kit (Thermo scientific) and qPCRs were performed using SYBR Green qPCR Mastermix (Bimake) on a BioRad CFX Connect thermocycler. Quantitative comparisons between immunoprecipitations and input samples were made using delta-delta Ct normalization, with GAPDH as a normalizing control.

Library preparation and sequencing {#s4-5}
----------------------------------

Total RNA quality was assessed by spectrophotometer (NanoDrop, Thermo Fisher Scientific Inc, Waltham, MA) and with an Agilent Fragment Analyzer (Agilent Technologies, Palo Alto, CA). All RNA samples had integrity scores greater than 9, reflecting high-quality, intact RNA. RNA sequencing libraries were generated using the Nugen Universal Plus mRNA-Seq kit with multiplexing primers, according to the manufacturer's protocol (NuGen Technologies, Inc, San Carlos, CA). Fragment size distributions were assessed using Agilent's Fragment Analyzer DNA high-sensitivity kit. Library concentrations were measured using KAPA Library Quantification Kits (Kapa Biosystems, Inc, Woburn, MA). Equal amounts of indexed libraries were pooled and single-end 50 bp sequencing were performed on the Illumina HiSeq 4000 at the UCSF Center for Advanced Technology (CAT) (<http://cat.ucsf.edu>).

RNA sequencing analysis {#s4-6}
-----------------------

Raw reads were pseudo-mapped to the mouse transcriptome using Salmon 0.13.1 ([@bib39]). Quantified transcripts were passed to Tximport 1.12 for gene-level summarization and differential expression analysis was performed with DESeq2 1.24, using alpha = 0.05 ([@bib33]; [@bib34]). Genes with total read counts below 20 in all samples were eliminated from the analyses. Data have been submitted to the Gene Expression Omnibus (GEO) repository for datasets; the accession number for this dataset is: GSE138333.

MCAO {#s4-7}
----

MCAO was performed in spontaneously breathing animals anesthetized with 3% isofluorane in 100% O~2~. The right internal carotid artery (ICA) was dissected and a temporary ligature was tied using a strand of 6--0 suture at its origin. This ligature was retracted laterally and posteriorly to prevent retrograde blood flow. A second suture strand was looped around the ICA above the pterygopalatine artery and an arteriotomy was made proximal to the isolated ICA. A silicone coated 6--0 nylon filament from Doccol Corporation (Sharon, MA, USA) was inserted 5 mm to occlude the MCA and the second suture strand was tied off to secure the filament for the duration of occlusion. Following recovery from anesthesia, mice were returned to their cage for the 90 min duration of the occlusion. Injury was confirmed by severe left frontal/hindlimb paresis resulting in circling movements during the occlusion period. For reperfusion, each animal was anesthetized and all suture ties and the occluding filament were removed. Avitene Microfibrillar Collagen Hemostat (Warwick, RI, USA) was placed over the arteriotomy and the skin incision was closed. Staining for P2RY12, TMEM119, and CXCL10 was performed as described in 'Immunohistochemistry'.

EAE {#s4-8}
---

*P2ry12-CreER; Rosa26^Ai14^;Cx3cr-1-EGFP* mice (C57BL/6 background) were subcutaneously injected with 200 µl of an emulsion of Complete Freund's adjuvant, MOG35-55 peptide, and inactivated mycobacterium tuberculosis (EK-2110; Hooke Laboratories). 2 hr and 24 hr afterwards, 200 ng of Pertussis toxin was injected i.p. (EK-2110; Hooke Laboratories). At 10 d after onset of symptoms, mice were perfused (see Histology and immunostaining above). Following perfusion, spinal cords were dissected and incubated in 30% sucrose, overnight. The following day, spinal cords were frozen in OCT and 20 µm sections were generated. Staining for PU.1, and EGFP was performed as described in 'Immunohistochemistry'.

Imaging {#s4-9}
-------

Confocal images were taken using a motorized Zeiss 780 upright laser scanning confocal microscope with a 34 detector array with a water immersion Zeiss Plan Apochromat 20X/1.0 D = 0.17 Parfocal length 75 mm (Zeiss, Germany). Images for [Figure 2](#fig2){ref-type="fig"} and [Figure 3C](#fig3){ref-type="fig"} were taken with a Zeiss Axio Imager.Z2 epifluorescent microscope.

Statistical analysis {#s4-10}
--------------------

Sample size was not precalculated using a statistical framework, but conformed to general standards in the field. Sample analysis was not blinded. For all immunostaining quantification, values for each mouse were calculated by averaging three pictures from each mouse. For flow cytometry in [Figure 4D](#fig4){ref-type="fig"}, four separate mice were used per genotype. Differences between means were compared using a two-tailed t-test, with an alpha of 0.05. For statistical analysis in [Figure 1---figure supplement 1A, C](#fig1s1){ref-type="fig"}, a One-Way ANOVA with a Tukey's multiple comparisons test was performed, with an alpha of 0.05.

For ribosomal immunoprecipitations, three samples were prepared, each of which was derived from a separate single mouse brain preparation (three immunoprecipitations from three separate mouse brains). Input samples were created by collecting 80 µL samples of supernatant from each of these brain preparations, prior to immunoprecipitation. Samples from separate mice were considered biological replicates. We did not eliminate any samples as outliers from our analysis. Differences in gene expression were tested using DESeq2, with an alpha of 0.05, with sample pairing in the model.
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###### DeSeq2 source code.

Source code used for differential expression analysis. For details, please see [@bib33], [@bib34].

###### Salmon pseudomapping source code.

Source code used for mapping reads to mouse transcriptome. For details, please see [@bib39].

###### Microglial markers analyzed in Tabula Muris.

A short list of microglial enriched genes that were analyzed in the Tabula Muris. Of these genes, *P2ry12* was selected for further analysis.

###### Results of comparative DESeq2 analysis of *P2ry12-CreER* and *Cx3cr1-CreER* ribosomal immunoprecipitations.

For details please see 'RNA sequencing analysis' section in Materials and methods section.

###### CNS border-associated macrophage (BAM) recombinase lines.

A short list of BAM-targeting recombinase and DTR lines.
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Sequencing data have been submitted to the Gene Expression Omnibus (GEO) repository for datasets. The accession number for this dataset is: GSE138333.

The following dataset was generated:

McKinseyGSantanderNArnoldT2020Translational profiling of microgliaNCBI Gene Expression OmnibusGSE138333

The following previously published dataset was used:

HaimonZVolaskiAOrthgiessJBoura-HalfonSVarolDShemerAYonaSZuckermanBDavidEChappell-MaorLBechmannIGerickeMUlitskyIJungS2018Re-evaluating Microglia Expression Profiles Using RiboTag and Cell Isolation StrategiesNCBI Gene Expression OmnibusGSE114001
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Microglia are the resident immune cells of the central nervous system that play critical roles in development, homeostasis and inflammation. This study reports the generation of *P2ry12-CreER* mice as a useful new tool to genetically target and study microglia biology. The authors used these mice to track microglia during development, following injury and inflammation.

**Decision letter after peer review:**

Thank you for submitting your article \"New tools for genetically targeting myeloid populations in the central nervous system\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, including Isaac M Chiu as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Beth Stevens (Reviewer \#3); Amanda Sierra (Reviewer \#4).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Microglia are important cells that regulate CNS homeostasis, immunity, and neurodegeneration. This manuscript provides an interesting new tool, the *P2RY12-CreER* mice to specifically label and target microglia and not other brain macrophages (meninges, choroid plexus, perivascular space). Once validated, this resource would be widely used in the field and the authors plan to make this new line available at Jackson Labs. All reviewers were enthusiastic about this new resource and mouse tool for the field. Although the data shown look promising, a more thorough validation and characterization of this new mouse line is needed. In particular, the authors must put a strong effort into actually quantifying the percentage of cells labeled/targeted in each experiment, instead of using terms such as \"widespread or sparse labeling\". There were also missing pieces of information on methodology used and references that should be addressed before publication. We list the concerns below.

Essential revisions:

1\) Given the leakiness of some *CreER* strains in combination with certain reporter lines (see Van Hove et al., 2019 and Chappell-Maor et al., 2019), it is critical to analyze the recombination of microglia in *P2ry12-CreER Ai14* mice also without tamoxifen treatment.

2\) More rigorous quantification and assessment of recombination in BAMs.

Perivascular macrophages can be interrogated in brain sections by IHC, but to achieve a complete assessment of the meningeal BAMs, the meninges need to be removed from inside of the skull. Only the pia layer of the meninges stays adhered to the brain when the skull is removed. LYVE1 is also not an appropriate marker for labeling of BAMs as it only labels a subset. Importantly, dounce homogenization followed by percoll purification is not an appropriate method for isolating BAMs and the expression of TdTomato in other cells than microglia can therefore not be quantified correctly using these approaches.

3\) Effect on P2RY12 protein expression and function.

Figure 1A: The authors use single examples of immunostaining against P2RY12 to demonstrate that the *P2ry12-CreER* mouse has normal P2RY12 protein expression. However, this claim should be supported by quantification, and immunohistochemistry is not a sensitive method for measuring protein levels. It will be critical to validate that the P2RY12 protein expression in the *P2ry12-CreER* mice is similar to WT mice with and without tamoxifen treatment. This is straightforward as there are antibodies against P2RY12 commercially available for flow cytometry. Additionally, the P2RY12-dependent motility of microglial processes in the *P2ry12-CreER* mouse should be assessed. Over the last decade, evoking laser-induced injuries has become a standard paradigm in many labs that are studying microglia.

4\) Effect on P2ry12 transcription.

Based on the (n=1) ribosomal immunoprecipitations, the *p2ry12* transcriptions might appear to be normal and based on this one example. It would be helpful if the authors could quantify P2ry12 transcript levels using qRT-PCR to confirm that the presence of the *P2ry12-CreER* allele does not impact expression of the gene.

5\) Reproducibility of Ribosomal immunoprecipitations experiment.

This experiment is elegant and support the conclusion that *P2ry12-CreER* is selective to microglia. However, is this (n=1) experiment reproducible? Please repeat for a minimum of 3 replicate experiments. It would be very powerful to also perform ribosomal immunoprecipitation on the meninges.

6\) In Figure 1B, CD11b and CD45 does not suffice to detect non-parenchymal macrophages by flow cytometry. CD11bhi cells also comprise monocytes, neutrophils, some cDCs and conversely, some borderzone macrophages are CD45low. More markers should be included to identify borderzone macrophages.

7\) In Figure 1C, what is the percentage of microglia, borderzone macrophages and monocytes that are TdTomato+ in *P2ry12-CreERAi14* mice by flow cytometry?

8\) In Figure 1E-G, the images suggest that *P2ry12-CreER;Ai14* recombination does not occur in perivascular or meningeal macrophages, nor in non-macrophage cells in the brain, but can be detected in choroid plexus macrophages. These conclusions should be supported by quantification, either of immunohistochemistry images, or of FACS data. In Figure 1G, what are the TdTomato+ cells in *P2ry12-CreER*; *Ai14* mice (Iba1-) in the choroid plexus?

9\) In Figure 2, the authors describe recombination in *P2ry12-CreER*; *Ai14* embryos in microglia, in choroid plexus macrophages and also in some meningeal macrophages. Are perivascular macrophages also labeled? Also here, the images should be quantified. Are macrophages in other embryonic tissues also TdTomato+ or just brain macrophages? It seems that this *CreER* strain is not microglia-specific during embryogenesis. This should be discussed in more detail. They should discuss their model also in the context of other previously described models to target microglia (for example Kaiser et al., 2019).

10\) Analyses and quantification of recombination in other organs.

In Figure 3, what is the percentage of the macrophages positive for TdTomato in the different organs? This should be quantified (FACS or immunohistochemistry). Where are they located (associated to vessels, peripheral nerves)? The authors state that recombination in tissue-resident macrophages in peripheral organs is "limited" even though they provide images of TdTomato expression in both the spleen, lung, heart, thymus, intestine, and liver. Some level of quantification should be provided to support that this expression is "limited" and negligible. The recombination in the brains of these mice (n = 3 or higher) should also be measured as a positive control to demonstrate high recombination efficiency.

11\) In Figure 3A, there seems to be TdTomato expression in neurons. Can the authors comment on this or provide higher magnification images to exclude co-expression?

12\) In Figure 3C, it is not clear why the cells are yellow as there is no GFP.

13\) Some microglia signature genes including P2ry12 are downregulated upon microglia activation and in disease. Can this strain be utilized to target activated microglia?

14\) P2ry12 is also highly expressed by platelets. Do the authors find evidence that megakaryocytes are targeted with the *P2ry12-CreER*;*Ai14* mice?

15\) They show that with Pf4-Cre mice borderzone macrophages can be targeted. This needs better characterization and should be quantified. Are monocytes, tissue macrophages in other organs, or any other cells also labeled?

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for re-submitting your article \"A New Genetic Strategy for Targeting Microglia in Development and Disease\" for consideration by *eLife*. Your article has been re-reviewed by three peer reviewers, including Isaac M Chiu as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Amanda Sierra (Reviewer \#4).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

This study has developed *P2ry12-CreER* mice to genetically mark and target microglia, which are resident immune cells of the CNS. The authors were able to use these mice to distinguish microglia from border associated macrophages, and to track microglia during development and following injury and inflammation. This could be a broadly useful tool for the neuroscience field to study microglial biology and function.

Revisions:

All the reviewers agree that the authors have done a good job addressing the points raised. Major concerns regarding the need for proper cell quantification have been met. Nomenclature issues have been addressed. The Discussion now properly takes into account the comparison with other mouse lines available.

There is only one comment that should be addressed:

Regarding point 13) in their response letter:

They clearly demonstrate that microglia are efficiently (irreversibly) labeled with their strain, and hence previously labeled microglia will remain labeled also in disease models. My earlier question was whether microglia can be labeled/manipulated in an inducible manner once they are reactive i.e. during the course of an inflammatory disease. Given that P2ry12 is downregulated in reactive microglia, the question remains whether levels of Cre are nonetheless sufficient to allow targeting of microglia in inflammation in *P2ry12-CreER* mice. (For example, tamoxifen injection in EAE-diseased animals at peak disease). If they don\'t have this data, it should at least be discussed.

10.7554/eLife.54590.sa2

Author response

> Essential revisions:
>
> 1\) Given the leakiness of some CreER strains in combination with certain reporter lines (see Van Hove et al., 2019 and Chappell-Maor et al., 2019), it is critical to analyze the recombination of microglia in P2ry12-CreER Ai14 mice also without tamoxifen treatment.

We thank the reviewer for this suggestion. We performed these experiments and found that there is very low (but not zero) recombination in the absence of tamoxifen using the Ai14 reporter line. We observed a non-tamoxifen recombination rate of 0.38%, or about 1 in every 263 microglia (see Figure 1---figure supplement 1D). Given the sensitivity of the Ai14 reporter allele (Alvarez-Aznar et al., 2020), we believe that this recombination frequency is likely to be lower for other floxed alleles.

> 2\) More rigorous quantification and assessment of recombination in BAMs.
>
> Perivascular macrophages can be interrogated in brain sections by IHC, but to achieve a complete assessment of the meningeal BAMs, the meninges need to be removed from inside of the skull. Only the pia layer of the meninges stays adhered to the brain when the skull is removed. LYVE1 is also not an appropriate marker for labeling of BAMs as it only labels a subset. Importantly, dounce homogenization followed by percoll purification is not an appropriate method for isolating BAMs and the expression of TdTomato in other cells than microglia can therefore not be quantified correctly using these approaches.

We very much appreciate these suggestions. We have removed flow cytometry data of macrophages other than microglia (CD11b^+^CD45^int^ cells). Regarding recombination in BAMs, we have generated new pia mater and dura mater whole-mount data from *P2ry12-CreER; Ai14* mice. Labeling these preparations (and thin coronal sections to visualize perivascular macrophages) for two different BAM markers, LYVE1 and CD206, we found that *P2ry12-CreER* does not recombine perivascular or subdural BAMs, but does recombine a subset of CD206+ BAMs in the dura, some of which were also LYVE1+ (Figure 2, Figure 2---figure supplement 2). Our results are consistent with single cell sequencing (Van Hove et al., 2019) which showed low (but not zero) expression of *P2ry12* in meningeal BAMs compared to microglia and CPepi cells (see point 8, below), and with our RiboTrap data which show minimal enrichment of BAM transcripts in immunoprecipitations from *P2ry12-CreER; Rpl22-HA* mice. Importantly, the dura was not separately analyzed in our RiboTrap preparations which would explain why we don't see enrichment for dural BAM markers in these experiments despite seeing recombination of some dural BAMs in our whole-mount preparations.

> 3\) Effect on P2RY12 protein expression and function.
>
> Figure 1A: The authors use single examples of immunostaining against PR2Y12 to demonstrate that the P2ry12-CreER mouse has normal P2RY12 protein expression. However, this claim should be supported by quantification, and immunohistochemistry is not a sensitive method for measuring protein levels. It will be critical to validate that the P2RY12 protein expression in the P2ry12-CreER mice is similar to WT mice with and without tamoxifen treatment. This is straightforward as there are antibodies against P2RY12 commercially available for flow cytometry.

We thank the reviewers for this suggestion. We performed quantitative PCR for *P2ry12* from brains of wild type, heterozygous and homozygous *P2ry12-CreER* mice. We did find a reduction of *P2ry12* mRNA expression in homozygous knock-in mice (please see Figure 1---figure supplement 1A). To test whether this RNA reduction resulted in a reduction in translated protein, we analyzed P2RY12 protein levels in wild-type and homozygous mutant mice, with or without tamoxifen (Figure 1---figure supplement 1B-C). Here, we saw no significant change in P2RY12 protein level in the homozygote mouse, with or without tamoxifen treatment. From this analysis, we conclude that although there is a reduction in *P2ry12* mRNA expression in homozygous knock-in mice, this does not result in a significant change in P2RY12 protein levels.

> Additionally, the P2RY12-dependent motility of microglial processes in the P2ry12-CreER mouse should be assessed. Over the last decade, evoking laser-induced injuries has become a standard paradigm in many labs that are studying microglia.

We appreciate this suggestion. Because P2RY12 protein expression is not affected by gene targeting (see above), we believe P2RY12-dependant processes motility is unlikely to be affected in *P2ry12-CreER* mice. However, we did not test process motility directly. While important, we believe that the suggested experiments are beyond the immediate scope of this manuscript -- establishing laser-induced injury and live 2-photon microscopy protocols will take several months and require new animal (IACUC) approval.

> 4\) Effect on P2ry12 transcription.
>
> Based on the (n=1) ribosomal immunoprecipitations, the p2ry12 transcriptions might appear to be normal and based on this one example; It would be helpful if the authors could quantify P2ry12 transcript levels using qRT-PCR to confirm that the presence of the P2ry12-CreER allele does not impact expression of the gene.

We apologize for the confusion around our ribosome immunoprecipitation protocol. We in fact performed 3 separate immunoprecipitations, each from individual recombined *P2ry12-CreER;Rpl22-HA* mice (3 IPs total, one mouse brain per IP). Three separate libraries were generated from these immunoprecipitations, which were then sequenced along with libraries derived from 3 input controls from the three separate brain lysates prior to immunoprecipitation.

To more quantitatively measure *P2ry12* transcript levels, we performed qPCR analysis as suggested. We observed a reduction in *P2ry12* mRNA in homozygous knock-in mice compared to controls, but no significant difference in P2RY12 protein expression between these same groups (please see Figure 1---figure supplement 1A and response to point \#3 above).

> 5\) Reproducibility of Ribosomal immunoprecipitations experiment.
>
> This experiment is elegant and support the conclusion that P2ry12-CreER is selective to microglia. However, is this (n=1) experiment reproducible? Please repeat for a minimum of 3 replicate experiments.

We apologize for the confusion here. As described above (point 4), we in fact performed 3 separate immunoprecipitations, each from individual recombined *P2ry12-CreER;Rpl22-HA* mice (3 IPs total, one mouse brain per IP).

> It would be very powerful to also perform ribosomal immunoprecipitation on the meninges.

We absolutely agree. As discussed above, we observed *P2ry12-CreER* recombination in LYVE1+ and CD206+ dural macrophages. We would like to transcriptionally profile these cells and compare to *Pf4-Cre* and *Lyve1-Cre* recombined dural, subdural and perivascular macrophages to begin to understand the heterogeneity and transcriptional programs of these BAMs. This will be a focus of future work.

> 6\) In Figure 1B, CD11b and CD45 does not suffice to detect non-parenchymal macrophages by flow cytometry. CD11bhi cells also comprise monocytes, neutrophils, some cDCs and conversely, some borderzone macrophages are CD45low. More markers should be included to identify borderzone macrophages.

Thank you for this suggestion. Our new whole-mount immunohistochemistry and labeling with CD206 and LYVE1 (Figure 2 and Figure 2---figure supplement 2) clearly identifies distinct BAM populations (meningeal -- dural/subdural; perivascular; choroid plexus) and shows that *P2ry12-CreER* preferentially targets microglia, and a subset of choroid plexus and dural BAMs, but not other BAM populations. This result is further supported by our ribosome IP sequencing data. We have removed our flow cytometry analysis of non-parenchymal macrophages.

> 7\) In Figure 1C, what is the percentage of microglia, borderzone macrophages and monocytes that are TdTomato+ in P2ry12-CreER Ai14 mice by flow cytometry?

By flow cytometry, the recombination percentage of microglia is 94.8% (Figure 1) and the recombination percentage of circulating monocytes is 0.0175% (Figure 4D). We have removed our flow cytometry analysis of percoll-purified BAMs, but histologically we do not see any recombination in perivascular or pial BAMs (see Figure 2 and Figure 2---figure supplement 2). We do however see some *P2ry12-CreER; Ai14* recombination in dural and choroid plexus macrophages (see Figure 2).

> 8\) In Figure 1E-G, the images suggest that P2ry12-CreER; Ai14 recombination does not occur in perivascular or meningeal macrophages, nor in non-macrophage cells in the brain, but can be detected in choroid plexus macrophages. These conclusions should be supported by quantification, either of immunohistochemistry images, or of FACS data.

We agree with this conclusion, and have added quantification of immunohistochemistry images (please see Figure 2) to provide further support.

> In Figure 1G, what are the TdTomato+ cells in P2ry12-CreER; Ai14 mice (Iba1-) in the choroid plexus?

This is a very interesting question. We believe that these cells are CPepi (Kolmer's epiplexus) cells. We have performed a deeper, more quantitative analysis of *P2ry12-CreER; Ai14* recombination in the adult choroid plexus and have found that all recombined cells are IBA1(+) (see Figure 2). Similar to *Sall1-CreER* (as presented in Van Hove et al., 2019), and in contrast to *Cx3cr1-CreERT2*, which recombines all IBA1+ macrophages in the choroid plexus (see Figure 4---figure supplement 1), we found that *P2ry12-CreER* labeled a subset of IBA1+ CP macrophages on the apical surface of the CP. Van Hove et al. identified several transcripts enriched in putative CPepi-BAMs, including *Clec7a* (also enriched ribosomal IPs from *P2ry12-CreER; Rpl22-HA* mice) and *P2ry12*. Together, these data would suggest that *P2ry12-CreER* recombines CPepi BAMs. It is important to note that in Van Hove et al., 2019, *Sall1-CreERT2* appears to recombine many additional non-macrophage (IBA1-) cells in the wall of the lateral ventricle and choroid plexus stroma (small round cells), whereas *P2ry12-CreER* recombines only IBA1+ cells in the choroid plexus, speaking to the greater specificity of *P2ry12-CreER* recombination.

> 9\) In Figure 2, the authors describe recombination in P2ry12-CreER; Ai14 embryos in microglia, in choroid plexus macrophages and also in some meningeal macrophages. Are perivascular macrophages also labeled?

Yes, in embryos we did see recombination in SMA-adjacent CD206+ macrophages. Please see Figure 3E and discussion below.

> Also here, the images should be quantified.

Thank you for this suggestion. We have quantified the % recombination of embryonic meningeal and choroid plexus BAMS in embryos (see Figure 3). As the presence of SMA-coated arteries is very low at the time point we analyzed (E18.5), and the occurrence of CD206+ or LYVE1+ recombined cells is also very low (see Figure 3G), we were unable to quantify perivascular recombination in embryos.

> Are macrophages in other embryonic tissues also TdTomato+ or just brain macrophages?

We observed no recombination in embryonic liver or heart. Recombination was low in the embryonic intestine (3.2% of CD206+ cells and 8.2% of IBA1+ cells) and lung (3.2% of CD206+ cells and 5.5% of IBA1+ cells)(see Figure 4---figure supplement 2).

> It seems that this CreER strain is not microglia-specific during embryogenesis. This should be discussed in more detail.

Based on our immunostaining, there appears to be a population of cells recombined by *P2ry12-CreER* during embryogenesis that are outside of (but adjacent to) the brain parenchyma. These cells express BAM markers, such as LYVE1 and CD206, and are found in the meningeal space or around aSMA+ vessels (Figure 3D,H). We also see recombination in embryonic IBA1+ cells of the choroid plexus (Figure 3E). Within the brain parenchyma, there is a notable population of *P2ry12-CreER;Ai14* recombined cells that are also CD206+. These cells are most prominent at the junction of the developing dentate gyrus and the meninges overlying the hippocampus (Figure 3G). These CD206+ recombined cells are most concentrated at this position, but form a continuous "stream" through the embryonic subventricular zone (SVZ), although the fraction of CD206+ recombined cells diminishes with greater distance from the hippocampus. Hammond et al. recently described a population of Ms4a-expressing embryonic microglia which co-express both BAM (e.g. *Mrc1*, *CD206*) and microglia (e.g. *P2ry12*, *Fcrls*) transcripts. We speculate that these cells could be described by different models: (1) Embryonic LYVE1+ and CD206+ meningeal macrophages may express *P2ry12* while in border regions, and then die or downregulate BAM genes as they enter the brain parenchyma and become microglia. (2) Some small fraction of cells that will eventually become pial and perivascular macrophages may transiently express *P2ry12* during development and thus be recombined at this time point, (3) These cells may transiently express *P2ry12* while transitioning from microglia to dural BAM state/location, or (4) These cells may express *P2ry12* while in BAM regions and maintain *P2ry12* expression and positioning in these regions (dural BAMs and CPepi cells). The turnover and exchange of BAMs and microglia into and out of their specific niches, and the gene expression programs that these cells adopt, could in theory be quite dynamic. We discuss these findings and models in the Discussion. In the future, we plan to perform more detailed lineage tracing and ablation experiments (beyond the scope of this manuscript) to evaluate these different possibilities.

> They should discuss their model also in the context of other previously described models to target microglia (for example Kaiser et al., 2019).

We agree that this is important topic; we have created a separate Discussion section to more explicitly compare these various models.

> 10\) Analyses and quantification of recombination in other organs.
>
> In Figure 3, What is the percentage of the macrophages positive for TdTomato in the different organs? This should be quantified (FACS or immunohistochemistry). Where are they located (associated to vessels, peripheral nerves)? The authors state that recombination in tissue-resident macrophages in peripheral organs is "limited" even though they provide images of TdTomato expression in both the spleen, lung, heart, thymus, intestine, and liver. Some level of quantification should be provided to support that this expression is "limited" and negligible. The recombination in the brains of these mice (n = 3 or higher) should also be measured as a positive control to demonstrate high recombination efficiency.

We appreciate this suggestion and have now added quantification of Cx3cr1-EGFP+ and CD206+ recombined cells in various organs from *P2ry12-CreER;Ai14;Cx3cr1GFP* mice. All of these mice had high levels of microglial recombination (over 90%), but recombination in CD206+ or Cx3CR1-EGFP+ cells was low (quantification in Figure 4C). The most significant recombination observed in non-neural tissue was in the marginal zone of the spleen (Figure 4B,C and lower magnification of spleen recombination in images Figure 4---figure supplement 1).

SMA staining in the liver suggests that recombined cells are specifically not associated with SMA+ vessels, unlike *Cx3CR1-EGFP* expressing cells (see Figure 4---figure supplement 1C). In the lung however, recombined cells were specifically associated with SMA-associated airways, or airway adjacent blood vessels (Figure 4---figure supplement 1D). We have not yet had the opportunity to examine whether *P2ry12-CreER; Ai14* recombination is associated with peripheral nerves in these organs.

> 11\) In Figure 3A, there seems to be TdTomato expression in neurons. Can the authors comment on this or provide higher magnification images to exclude co-expression?

Thank you for pointing this out. High magnification images with DAPI show that these are overlapping cells from thick optical sections, and not the same cell (please see new images in Figure 4). Also, please note that neuronal transcripts are specifically depleted in our ribosome IP RNA sequencing data.

> 12\) In Figure 3C, it is not clear why the cells are yellow as there is no GFP.

Thank you for pointing this out. This was a problem with the processing of the image, and this did not reflect actual expression of EGFP. We have corrected the figure.

> 13\) Some microglia signature genes including P2ry12 are downregulated upon microglia activation and in disease. Can this strain be utilized to target activated microglia?

Indeed! Using two different models of injury/inflammation (MCAO stroke and EAE), we have found that *P2ry12-CreER* mice can be used to label what we assume are resident microglia that are responding to injury (inside or near lesion; tdT+P2RY12-TMEM119-) or maintain homeostatic signature (away from lesion; tdT+P2RY12+TMEM119+). We have added these experiments to the manuscript as new Figures 7 and 8, for the MCAO and EAE data respectively.

> 14\) P2ry12 is also highly expressed by platelets. Do the authors find evidence that megakaryocytes are targeted with the P2ry12-CreER;Ai14 mice?

Blood preparations from induced *P2ry12-CreER;Ai14* and *Pf4-Cre;Ai14* mice (well known to recombine platelets) were stained for platelet marker CD41. Although we saw robust labeling of platelets in *PF4-Cre; Ai14* mice, we saw no recombination of platelets in *P2ry12-CreER* mice (see Figure 4). We also found no enrichment for platelet markers in our ribosome sequencing experiments.

> 15\) They show that with Pf4-Cre mice borderzone macrophages can be targeted. This needs better characterization and should be quantified. Are monocytes, tissue macrophages in other organs, or any other cells also labeled?

This mouse line has been well characterized for recombination in monocytes and organ macrophages outside of the CNS (Calaminus et al., 2012, Abram et al., 2014). We have now quantified recombination in BAMs using various markers and whole-mount preparations (Figure 6).

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Revisions:
>
> All the reviewers agree that the authors have done a good job addressing the points raised. Major concerns regarding the need for proper cell quantification have been met. Nomenclature issues have been addressed. The Discussion now properly takes into account the comparison with other mouse lines available.
>
> There is only one comment that should be addressed:
>
> Regarding point 13) in their response letter:
>
> They clearly demonstrate that microglia are efficiently (irreversibly) labeled with their strain, and hence previously labeled microglia will remain labeled also in disease models. My earlier question was whether microglia can be labeled/manipulated in an inducible manner once they are reactive i.e. during the course of an inflammatory disease. Given that P2ry12 is downregulated in reactive microglia, the question remains whether levels of Cre are nonetheless sufficient to allow targeting of microglia in inflammation in P2ry12-CreER mice. (For example, tamoxifen injection in EAE-diseased animals at peak disease). If they don\'t have this data, it should at least be discussed.

We apologize for not addressing this question in our previous response letter. Whether microglia can be targeted during inflammation is an important question. We suspect that *P2ry12-CreER* expression would be reduced in microglia responding to inflammation and that this would thus reduce the probability of tamoxifen-dependent recombination, but we have not yet tested this. We have added some discussion about this potential strategy in our Discussion section "*P2ry12-CreER* applications".
